Abcam, who earlier today disclosed it received strategic inquiries from multiple parties, has attracted interest from suitor including some of the largest U.S. suppliers of life-sciences tools and is in discussions on a potential sale, Michelle Davis and Dinesh Nair of Bloomberg report, citing people with knowledge of the matter. According to RBC, investors view Thermo Fisher Scientific (TMO), Danaher (DHR) and Merck KGaA (MKGAY) as the most likely bidders for Abcam, Bloomberg notes. Shares of Abcam are up 15% to $21.97 in afternoon trading.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABCM:
- Abcam Blasts Up on Word of Buyout Interest
- Abcam jumps 14% to $21.73 after disclosing multiple strategic inquiries
- Abcam says Milner’s plan ‘puts in jeopardy’ recent momentum
- Abcam received strategic inquiries ‘from multiple parties’
- AutoZone upgraded, SoFi downgraded: Wall Street’s top analyst calls